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The cell envelope of Gram-negative bacteria is a formidable biological barrier, 
inhibiting the action of antibiotics by impeding their permeation into the intracellular 
environment. In-depth understanding of permeation through this barrier remains a 
challenge, despite its critical role in antibiotic activity. We therefore designed a divisible 
in vitro permeation model of the Gram-negative bacterial cell envelope, mimicking its 
three essential structural elements – the inner membrane, the periplasmic space as 
well as the outer membrane – on a Transwell® setup. The model was characterized by 
contemporary imaging techniques and employed to generate reproducible quantitative 
and time-resolved permeation data for various fluorescent probes and anti-infective 
molecules of different structure and physicochemical properties. For a set of three 
fluorescent probes the permeation through the overall membrane model was found to 
correlate with in bacterio permeation. Even more interestingly, for a set of six 
Pseudomonas quorum sensing inhibitors, such permeability data were found to be 
predictive for their corresponding in bacterio activities. Further exploration of the 
capabilities of the overall model yielded a correlation between the permeability of porin-
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independent antibiotics and published in bacterio accumulation data; a promising 
ability to provide structure-permeability information was also demonstrated. Such a 
model may therefore constitute a valuable tool for the development of novel anti-
infective drugs.   
 
Keywords: Anti-infectives, drug delivery, drug design, Gram-negative bacterial cell 
envelope, in vitro model 
 
Infectious diseases caused by Gram-negative bacteria are becoming increasingly 
difficult to treat, due to the significant and evolving protective effect of the bacterial cell 
envelope.1 A comprehensive analysis has demonstrated that the major scientific 
obstacle to the discovery of novel, Gram-negative active antibiotics is an insufficient 
understanding of how to design molecules capable of overcoming this barrier.2, 3 The 
envelope itself consists of a largely phospholipid-based inner membrane (IM), a 
peptidoglycan-containing periplasmic space (PS), and an asymmetric outer membrane 
(OM) composed of a phospholipid-containing inner leaflet (IL) and a lipopolysaccharide 
(LPS)-based outer leaflet (OL).4 Clearly therefore, the Gram-negative cell envelope 
constitutes a complex and considerable physical barrier to the entry and subsequent 
action of anti-infectives.5  
Given that trafficking of anti-infectives into and across the envelope barrier is an 
essential requirement for their activity, the ability to assess anti-infective permeation in 
a quantitative, kinetically-resolved manner would offer considerable advantages.6 High 
content permeation information and the afforded ability to establish structure-
permeability relationships would represent valuable tools in the rational design and 
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optimization of anti-infectives7. This would additionally complement the assessment of 
drug-target interactions as well as classical efficacy testing such as the determination 
of minimum inhibitory concentrations (MIC).8 The use of bacterial cell assays, as the 
most representative means for assessing envelope permeation kinetics, is possible, 
but is hampered by considerable analytical and practical challenges.9 A wealth of in 
vitro envelope models is also available, generally grouped into the categories of 
Langmuir film-based models,10 electrophysiology models,11, 12 and vesicle-based 
assays.13 However, many of these existing models do not entirely approximate the 
double membrane structure of the cell envelope, or are composed of phospholipids 
which differ in either species or quantity from those found in Gram-negative bacteria. 
As a result, the majority of these existing models are not sufficiently representative of 
the overall envelope structure to allow for determination of envelope permeation 
kinetics, and additionally lack the level of robustness required for such investigations.12, 
14 A clear need therefore exists for in vitro models that are specifically designed and 
suited for the assessment of bacterial envelope permeation. Although transport 
processes in bacteria are mediated to a significant extent by transmembrane proteins, 
a method to assess passive diffusion processes across the envelope membranes was 
nevertheless hypothesized to be valuable, as it would allow for identification of 
compounds whose entry is (at least in part) protein-independent, or may become so 
due to saturation or downregulation. The ability to characterize passive envelope 
permeation independent of active protein-mediated transport could potentially also aid 
in the differentiation of compounds which are simply poorly permeable, from 
compounds which have an appreciable membrane permeability but do not appear to 
reach or be retained at their target site due to active efflux.  
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Having previously demonstrated the potential of such a setup by developing a model 
that assesses passive permeation across the bacterial IM alone,15 we herein report on 
the design of a divisible in vitro permeation model of the entire Gram-negative cell 
envelope. The model consists of IM and OM structures separated by a gel-based 
spacer as a surrogate for the PS. It was prepared stepwise by generating individual 
OM and PS structures, which were then combined with the previously developed IM 
model (Figure 1). Individual structures as well as the overall envelope model itself were 
fabricated by deposition on culture plate filter inserts of the Transwell® system − the 
membrane filter of which is commonly used to support mammalian cell monolayers 
employed in permeation studies.16 While entailing significant dimensional scale up (for 
instance in thickness) in comparison to native bacteria, the employment of a 
Transwell®-based modeling approach provides a solution to the aforementioned issues 
of robustness, resolution and quantification associated with existing cell-based and in 
vitro bacterial models.  
 
 
 
 
 
Figure 1. Schematic of the Gram-negative bacterial cell envelope and modeling 
approach. The envelope consists of the inner membrane (IM), the periplasmic space 
(PS) and the outer membrane (OM), with its phospholipid-containing inner leaflet (IL) 
and lipopolysaccharide (LPS)-containing outer leaflet (OL) (A). The individual modeling 
approach of each envelope component is shown (B); in addition, the overall envelope 
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model setup is depicted (C). In all cases, the antibiotic permeability can be assessed 
by addition of the drug to the apical compartment, followed by a quantification of drug 
concentration of basolateral compartment samples over time. 
 
 
Results and Discussion 
In the development of an OM model, it was aimed to mimic the asymmetric nature of 
IL and OL structures in order to obtain a functional similarity to the native OM. The 
modeling procedure consisted of two coating processes. First, Transwell® inserts were 
coated with a physiologically relevant 90:10 weight ratio of palmitoyl-oleoyl-
phosphatidylethanolamine (POPE) and palmitoyl-oleoyl-phosphatidylglycerol (POPG), 
as a composition representative of Escherichia coli,17 in order to form the IL (Figure 2A 
1). In a second step, LPS was deposited on top of the IL via a customized nebulization 
chamber, to form the OL component of the OM (Figure 2A 2). The OM model was 
characterized in terms of structure and suitability for transport experiments, prior to 
assessment of its functional similarity to the bacterial OM. An increase in z-dimension 
when comparing the IL+OL containing OM model with the IL structure alone was taken 
as a first indication of the successful deposition of an LPS layer (Figure S1). 
The integrity of the LPS-based OL (known to be chiefly responsible for OM barrier 
properties18) was confirmed via confocal laser scanning microscopy (CLSM) and found 
to be robust and stable for several hours under conditions of transport experiments 
(Figure S2). Correlative microscopy allowed for visualization of a sufficient coverage 
and distribution of LPS deposited on top of the phospholipids of the IL (Figure 2B-D). 
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Complementarily, the asymmetric structure of the entire OM could be clearly shown 
via CLSM (Figure 3 A-C).  
Transport studies with fluorescein, rhodamine 123 and rhodamine B isothiocyanate as 
permeability markers with varying lipophilicities (Table S1) confirmed the importance 
of combining IL and OL structures for achieving a functional OM surrogate, as 
significantly lower marker permeability was observed compared to experiments with 
the OL or IL alone (Figure S3). In order to investigate the specific functional similarity 
of the OM model to the native OM, the permeation of the aforementioned markers was 
measured in the presence of polymyxin B (PMB), a peptide known to permeabilize the 
native bacterial OM.19 An increased permeation was indeed observed for all three 
fluorescent dyes (Figure 3D). In a second step, the permeation of vancomycin, known 
to be inactive against Gram-negative bacteria due to its inability to cross the bacterial 
OM, was assessed.20 Permeation of vancomycin was found to be very low (< 0.3% 
after 2.5 h, in comparison to values of 2-8% for the fluorescent compounds - Figure 
S3), confirming a functional similarity of the OM model to the native OM. 
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Figure 2. Outer membrane model preparation and characterization. Schematic of the 
two-step preparation process of the OM model (A). Representative scanning electron 
microscopy (SEM, B) and CLSM images (C) of the OM, showing fluorescently-labeled 
LPS in green. The superimposed correlative microscopy image (D) shows a sufficient 
coverage of the phospholipid layer with LPS (in accordance with Figure S2) as well as 
some spot-wise accumulation, potentially as a result of the IL surface texture. 
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Figure 3. CLSM imaging and functional assessment of the OM. Using CLSM the 
orthographic projection of the OM model shows fluorescein isothiocyanate (FITC)-
labeled LPS of the OL in green and laurdan stained PLs of the IL in blue (A). 
Orthographic projection of the same sample, but on a lower level in z-direction, shows 
the separation of LPS of the OL from PL of the IL (B). This demonstrates the 
asymmetric structure of the OM model, which is also evident from the three-
dimensional view (C). The permeabilizing effect of PMB on the OM model is shown by 
the increased translocation of the three dyes (D), confirming functional similarity to the 
native OM. Values represent mean ± SE; n=9 from three independent experiments. 
Next, a PS model was prepared. The PS is not considered to constitute a diffusion 
barrier in the order of the IM and OM,21 but rather serves as a hydrophilic, viscous 
spacer compartment separating the two lipophilic membrane structures.4 An alginate 
gel layer was employed for this purpose. The suitability of this layer was tested in 
permeation studies using the two fluorescent probes fluorescein and rhodamine B 
isothiocyanate, which show different lipophilicities and charges at the experimental pH 
D B A 
C 
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of 7.4. Comparing their permeation through the gel to uncoated Transwell® inserts, as 
well as to OM and IM models, showed that although the permeation through the 
alginate gel is slightly lower compared to the blank Transwell® insert, its impact is still 
negligible compared to the significantly lower permeability across OM and IM model 
structures. The observed absence of a pronounced diffusion barrier property of the PS 
model compared to the IM and OM model hence demonstrates functional similarity of 
the PS model to the native PS. 
Figure 4. Permeated amounts of fluorescein (A) and rhodamine B isothiocyanate (B) 
across the PS model in comparison to an uncoated Transwell® membrane, the OM 
model and the IM model. Values represent mean ± SE; n=3 for PS model and blank 
A   Fluorescein 
B   Rhodamine B isothiocyanate 
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insert experiments; n=9 from 3 individual experiments for IM and OM model 
experiments. 
To obtain a model of the overall Gram-negative bacterial cell envelope, the previously 
developed IM was first deposited on a Transwell® insert; this was then overlaid with 
the gel of the PS, on top of which the OM was deposited. As demonstrated by SEM, 
the alginate layer utilized as the PS serves as a robust spacer between the IM and 
OM, without being affected by application of the OM (Figure S4). The three-layered 
structure of the entire envelope model was demonstrated by CLSM (Figure S5).  
Clearly, the value of such an in vitro model as a tool for optimizing anti-infective 
compounds strongly depends on the predictivity of obtained permeation data. In a first 
step towards gauging this value, we compared permeation data of fluorescent 
permeability markers in our in vitro model with cellular uptake data, obtained by 
quantifying compound translocation in E. coli by liquid chromatography-tandem mass 
spectrometry (LC-MS/MS). For this purpose, fluorescein, rhodamine 123 and 
rhodamine B were selected due to their different logDpH7.4 values and varying charges 
at pH 7.4 (Table S1). The initial employment of non-antibiotic permeability markers 
further allowed for specific assessment of bacterial uptake without the confounding 
effect of bacterial killing. An increase of permeation/uptake as a function of permeability 
marker lipophilicity was observed in both the in vitro envelope model after 4.5 h of 
permeation studies, and in the E. coli cellular model; furthermore, the degree of marker 
uptake in bacterio showed similar levels to the percentage of compound permeation 
across the in vitro model (Figure 5A). In contrast to these rather cumbersome bacterial 
uptake studies, which may only provide a single data point due to their destructive 
nature, the new in vitro model allows for ready generation of time-resolved kinetic data 
of such permeation processes (Figure 5B).  
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Figure 5. Comparison of permeability of marker compounds across the in vitro 
envelope model with uptake into E. coli. Permeability experiment results reveal 
comparable levels of uptake/permeation (A), while kinetic profiles of marker 
permeation highlight the ability of the in vitro envelope model to provide time-resolved 
permeation data (B). Values represent mean ± SE; n=6 from two independent 
experiments. 
In a second step, we selected a set of in-house synthesized quorum sensing inhibitors 
for permeation testing (Table 1, Figure S6). This new class of anti-infectives interferes 
with bacterial cell-to-cell communication and virulence by inhibiting the key signal 
molecule synthase PqsD of the human pathogen Pseudomonas aeruginosa.22 This 
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results in a reduced production of quorum sensing signals and related effector 
molecules.23, 24 PqsD inhibitors constitute an interesting group of compounds for testing 
in the overall envelope model, as they must permeate across the entire bacterial cell 
envelope in order to reach their intracellular target and do not affect bacterial growth. 
The selected compounds are of particular interest, as they exhibit comparable IC50 
values at their molecular target in vitro, but in some cases (compounds 1 and 2) no in 
bacterio activity, represented by an absence of HHQ inhibition (Table 1).25 
Table 1. Important physicochemical parameters and activity in cell-free and cellular 
assays of PqsD inhibitors.  
Compound
 
Mw 
(g/mol) 
logPa IC50  
(µM)a 
HHQ 
inhibition 
(%)a,b 
% permeated 2.5h 
(overall envelope 
model)c 
1, R = n-pentyl 223.27 3.24 1.0 no  
inhibition 
Not detectable 
2, R = n-butyl 209.24 2.72 2.9 no 
inhibition 
2.3 ± 0.2 
3, R = n-propyl 195.22 2.17 1.0 22 4.7 ± 0.4 
4, R = ethyl 181.19 1.64 0.8 61 8.9 ± 0.9 
5, R = methyl 167.16 1.11 0.8 26 9.2 ± 0.4 
6, R = H 153.14 0.76 0.7 13 12.8 ± 0.7 
[a] Values from Storz et al.25 [b] Readout for compound efficacy, determined in 
P. aeruginosa PA14 pqsH mutant at inhibitor concentrations of 250 µM. No inhibition 
was defined as <10 %. [c] Values represent mean ± SE, n=6 from 2 individual 
experiments. 
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The permeation behavior of compounds 1-6 was therefore tested in the overall 
envelope model, as a possible means of explaining observed differences in efficacy in 
spite of comparable target-based activity. Consistent with our hypothesis, PqsD 
inhibitors with HHQ inhibition and thus activity against P. aeruginosa (compounds 3, 4, 
5, and 6) showed a significantly higher permeability across the envelope model in 
comparison to the non-active compounds (1 and 2; Table 1; Figure 6A, B). The 
permeability of compound 1 was even below the limit of assay detection. Interestingly, 
in direct contrast to the permeation behavior of fluorescent permeability markers 
(Figure 5A), PqsD inhibitor lipophilicity tended to be inversely correlated with cell 
envelope permeability. This observation implies an impact of physicochemical 
parameters additional to lipophilicity on compound permeation. Of further interest was 
the lack of a clear correlation between greatest activity against P. aeruginosa and 
highest in vitro permeability – this valuable observation may indicate a contribution of 
active efflux systems. Clustering of PqsD inhibitors based on their activity against P. 
aeruginosa and model permeability (Figure 6C) does however allow for a clear 
differentiation of the investigated PqsD inhibitors into two groups – compounds with a 
low model permeability ~ no in bacterio activity, and compounds with high model 
permeability ~ in bacterio activity. This data demonstrates the importance of cell 
envelope permeability as a delimiter of intracellular activity, and points to the 
usefulness of such data for the optimization of novel anti-infective compounds.  
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Figure 6. Permeability investigations of PqsD inhibitors. Permeability of the compounds 
1-6 across the in vitro envelope model showing significantly higher permeation values 
in the case of in bacterio-active compounds in comparison to non-active ones (A). The 
depicted kinetic profiles highlight the ability of the overall envelope model setup to 
provide quantitative and kinetically-resolved permeation data (B). Compounds were 
furthermore clustered into two groups according to their permeation and their in 
bacterio activity (% HHQ reduction at a compound concentration of 250 µM) 
(C).Values represent mean ± SE; n=6 from two individual experiments, *** = P < 0.001. 
 
Further to the above findings, specific mention must be made of the fact that not all 
anti-infectives exhibit an activity which can be directly correlated to their membrane 
permeability. The influence of additional factors such as the intrinsic in vitro activity of 
anti-infectives, as well as their status as substrates of active efflux pumps, which are 
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not featured in the overall model in its current stage of development, must be also 
considered when evaluating anti-infective efficacy. This was demonstrated by 
additional permeability investigations utilizing a set of in house-synthesized RNA 
polymerase (RNAP) inhibitors (Table S4, Figure S6).  
At this stage, as it had been noted that the structure of the overall membrane model 
still appeared to feature a rather uneven surface (Figure 7A), the protocol for PS 
preparation was improved by nebulizing rather than pipetting the component calcium 
chloride solution onto filter inserts. This resulted in a more planar overall membrane 
structure (Figure 7B).  
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Figure 7. X-ray microtomographic images of the overall membrane model after the 
calcium chloride solution was pipetted (A) and after the calcium chloride solution was 
nebulized on top of the alginate gel (B). Nebulization according to the new protocol, 
thus led to a better separation of the three layers as well as the formation of a more 
even membrane structure. 
After this modification, the capabilities of the model were further explored by assessing 
the permeability of a number of established antibiotics. In this respect, the permeation 
of novobiocin, erythromycin and rifampicin – reported to be passively permeating, 
porin-independent substances26,27 – was investigated. The permeation of the 
established antibiotic tetracycline, known for its largely porin-dependent permeation,27-
30 was also determined. As depicted in Figure 8, novobiocin showed the lowest 
permeability of the porin-independent compounds, while erythromycin A (being the 
most abundant component of erythromycin) and rifampicin showed a higher and similar 
permeability. This is in nice agreement with a recently published study investigating 
A 
B 
IM 
PS 
OM 
OM 
PS 
IM 
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the accumulation of these compounds in porin-competent E. coli.7 The comparatively 
low degree of tetracycline permeation observed in the overall envelope model is also 
entirely in line with its documented reliance on porins in order to permeate across the 
Gram-negative cell envelope, and is additionally validated by a high degree of 
observed accumulation in porin-competent E. coli.7  
Figure 8. Permeability of the porin-independent antibiotics novobiocin, erythromycin A 
and rifampicin as well as the porin-dependent compound tetracycline across the 
improved overall envelope model. Compound characteristics can be seen in (A), with 
compound permeability shown in (B). [e] values represent mean ± SE. n10 from three 
individual experiments. 
Further steps towards the employment of the model for establishing structure-
permeability relationships were then taken, by probing the permeability of the 
structurally-related gyrase inhibitors ciprofloxacin, norfloxacin, pipemidic acid and 
nalidixic acid (Figure 9). Nalidixic acid showed by far the highest degree of permeation 
of the tested compounds, likely due to its status as the smallest molecule of the tested 
set. The observed permeabilities of ciprofloxacin, norfloxacin, pipemidic acid and 
nalidixic acid were observed to increase with decreasing molecular weight (Mw), 
A B 
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indicating a stronger influence of this parameter than of compound polarity (LogD, 
Figure 9A). It is furthermore noteworthy, that the permeability of nalidixic acid was 
considerably higher than for the other gyrase inhibitors. This may be explained by the 
fact that, in contrast to nalidixic acid, the most abundant species of the comparatively 
lower permeating compounds ciprofloxacin, norfloxacin and pipemidic acid at pH 7.4 
is the zwitterionic one.31,32 This corroborates the earlier reported inferior permeation of 
zwitterionic ciprofloxacin through a lipid layer compared to its neutral species.33 This 
permeation behavior through porin-free membranes is, however, in contrast to porin-
expressing E. coli, where a positive charge in particular seems to be necessary to allow 
for an enhanced access to the constriction region of the porins OmpF and OmpC.12, 34-
37 Although at this stage still lacking specific transporters, such as porins and efflux 
pumps, the data obtained with the present model illustrate the value of such an 
approach to exclude e.g. poorly permeable candidates at a rather early stage of drug 
development, or to further optimize the design of novel anti-infectives towards better 
permeability. 
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Figure 9. Permeation of structurally-related gyrase inhibitors in the improved overall 
envelope model. Compound structures and key physicochemical parameters are 
provided in (A), while compound permeability is shown in (B). [e] values represent 
mean ± SE. n11 from three individual experiments. 
In conclusion, we have realized a divisible in vitro model of the Gram-negative bacterial 
cell envelope, which allows for the collection of quantitative, time-resolved permeation 
data for anti-infective compounds. In the case of a set of innovative PqsD-inhibitors as 
well as a sample of established porin-independent antibiotics, overall envelope model 
permeability data could correctly predict in bacterio activity and bacterial accumulation 
respectively. Moreover, investigation of the permeability of a set of gyrase inhibitors 
showed a promising ability of the model to provide structure-permeability information. 
Further model development and optimization is currently ongoing in order to increase 
throughput capacity, to investigate quantitative structure permeability relationships and 
to incorporate porins as well as elements of active influx/efflux.  
 
 
 
 
 
A B 
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Methods 
 
A detailed presentation of all utilized materials, preparation and characterization 
procedures can be found in the Supporting Information.  
OM model preparation. Model preparation was optimized to obtain a structural mimic 
of the OM consisting of a phospholipid-containing IL overlaid by an LPS-containing OL. 
To form the IL, Transwell® filter inserts were coated in two cycles with 37.5 µL of a 
phospholipid mixture of POPE and POPG in a physiologically relevant 90:10 (weight) 
ratio,17, 38 with a drying step of 4 min at 55 °C using an incubator (Memmert UN75, 
Memmert GmbH & Co, KG; Schwabach, Germany) following each cycle. To prepare 
the OL, a 0.3 mg/mL LPS solution was then nebulized in five cycles onto the prepared 
IL structure, using an Aerogen Solo nebulizer (Aerogen Ltd, Galway, Ireland) together 
with an in-house developed nebulization chamber (see Supporting Information). A final 
drying step of 5 min at 55 °C was then employed. 
OM model structural characterization. Correlative microscopy was performed to 
evaluate the integrity of LPS coverage in OM models. Filter inserts supporting OM 
structures were cut out of plastic holder surrounds, and sputter coated with gold 
(Quorum Q150R ES, Quorum Technologies Ltd., East Grinstead, UK). The Shuttle & 
Find™ extension and specialized sample holder (Carl Zeiss Microscopy GmbH, 
Germany) were used to image samples using both CLSM (Zeiss LSM 710, Jena, 
Germany) and SEM (Zeiss EVO HD 15, Carl Zeiss AG, Oberkochen, Germany), 
without the need for further sample alteration when switching between imaging 
methods. Further detail may be found in the Supporting Information.  
CLSM was also used to further probe the OM structure, and in particular to confirm its 
asymmetric nature. The OM model was prepared as described above, employing 
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FITC-labeled LPS to form the outer leaflet (OL) and staining the IL with laurdan (ratio 
phospholipids to laurdan 400:1 mol/mol). Samples were subsequently cut out of the 
plastic holder support, attached to a glass slide using an adhesive fixing agent, and 
covered with a cover slip. Imaging was performed using a Zeiss LSM 710 Axio 
Observer (Carl Zeiss Microscopy GmbH, Jena, Germany; λexc= 405 nm and λem= 
457 nm in the case of laurdan and λexc= 488 nm and λem= 564 nm in the case of 
FITC-labeled LPS). 
OM model functional characterization. Transport studies were performed to 
investigate compound permeability through the OM. OM model-permeated amounts of 
fluorescent dyes (fluorescein sodium, rhodamine 123, and rhodamine B 
isothiocyanate, Table S1) were initially tested over an experimental period of 2.5 h (see 
Supporting Information for experimental details). OM transport studies employing PMB 
as a well-known bacterial OM permeabilizing agent were also conducted, to investigate 
the functional similarity of the OM model to the native bacterial OM. In this case, 
following equilibration in buffer, OM models were incubated for one hour with 500 µL 
of 1.53 mM PMB. Following removal of PMB solutions and washing, fluorescent dyes 
were added and their permeability assessed as described in the Supporting 
Information.  
PS model preparation. In what is referred to as the ‘standard protocol’, a 75 µL 
volume of a 2% (w/v) alginate solution was added onto Transwell® filter inserts 
followed by the addition of 25 µL of a 5% (w/v) calcium chloride solution. Filter inserts 
were then allowed to rest for at least 1 h at room temperature in order for gel formation 
to occur. An alteration to this protocol was later made (‘improved protocol’) in which 
five cycles of 100 µL of a 5% (w/v) calcium chloride solution was nebulized per 
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Transwell®. The 20x increased volume relative to that employed above was chosen to 
compensate for the deposition efficiency of ~5% of the nebulization chamber. 
PS model structural characterization. Transport studies using the PS model 
(standard preparation procedure) were carried out in order to confirm that this 
component did not constitute an appreciable barrier to compound permeation. 
Fluorescein and rhodamine B isothiocyanate were employed for this purpose as 
permeability markers with differing physical properties (Table S2). Transport 
experiments investigating the permeability behavior of both fluorescent dyes across 
blank Transwell® filter inserts as well as the PS model were performed as described 
above for the OM model (see above, as well as in the Supporting Information). 
Overall envelope model preparation. The IM model was prepared as previously 
described.15 The PS model was then prepared directly on top of the IM structure, as 
described above. The IL and OL components of the OM were subsequently prepared 
on top of the PS, resulting in an overall envelope model. 
Overall envelope model structural characterization. The structure of the overall 
envelope was characterized by X-ray microtomography employing beamline P05 
operated by HZG at the storage ring PETRA III of DESY, Hamburg. Therefore, the 
overall membrane was prepared using the standard and the improved protocol (see 
above) for the PS and subsequently fixed and stained by exposing the coated 
Transwells® for 2 h to a 1% (w/v) OsO4 solution. Afterwards, slices of 3 mm width and 
12 mm length were cut out and placed into a thin plastic tube of 3 mm in diameter. 
Samples were exposed to X-ray synchrotron radiation using a photon energy of 12 
keV. The tomographic reconstructions were performed from 1200 projections equally 
stepped while turning 180°. Visual data were processed employing VGSTUDIO MAX 
software, Volume Graphics GmbH, Heidelberg. 
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Overall envelope model functional characterization. The general procedure for 
permeability investigations in the OM model was also employed in the case of the 
overall envelope model. The permeation behavior of fluorescent dyes (fluorescein, 
rhodamine 123 and rhodamine B; Table S1), as well as that of in-house synthesized 
PqsD inhibitors (compounds 1, 2, 3, 4, 5 and 6, at a concentration of 400 µM in buffer 
with 2% DMSO) was investigated. Moreover, the permeation of two sets of clinically 
established antibiotics – novobiocin, rifampicin and erythromycin as porin-independent 
antibiotics and tetracycline as a porin-dependent control, and the gyrase inhibitors 
ciprofloxacin, norfloxacin, pipemidic acid and nalidixic acid – was determined. Details 
of transport study methodology and quantification of compound permeation can be 
found in the Supporting Information.  
In bacterio comparison – bacterial uptake studies. Intact E. coli (BW25113) cells, 
cultured as described in the Supporting Information, were incubated with 1 µM 
solutions of fluorescein, rhodamine 123 or rhodamine B for 30 min. Cell suspension 
samples were then centrifuged through a 1 M sucrose cushion to remove adherent 
dye; resulting cell pellets were then sonicated with a probe sonicator (Sonoplus mini 
20, Bandelin electronic GmbH Co. KG, Berlin, Germany) on ice in order to disrupt the 
bacterial cells. Following further centrifugation and extraction, internalized fluorescent 
dyes were quantified by LC-MS/MS, as detailed in the Supporting Information.  
Statistical Analysis. Where appropriate, presented numerical data represent mean ± 
standard error of the mean (SE). Student’s t-test was employed where relevant to 
evaluate significant differences (**=P < 0.01, ***=P<0.001). All tests were calculated 
using the software SigmaPlot version 12.5 (Systat Software, Inc., San Jose, California, 
USA). 
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Chemical structures. Structural formulae were created using ChemDraw® 
Professional Version 15.1.0.144 (PerkinElmer Informatics Inc., Waltham, MA, USA).  
 
Supporting Information 
Supporting Information Available: [Nebulization chamber characterization, OM model 
characterization, OM model transport experiments, robustness assessment of the PS 
model, structural assessment of the overall envelope model, overall envelope model 
transport experiments (RNAP inhibitors).] This material is available free of charge via 
the Internet at http://pubs.acs.org.   
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